Saturday 17 October 2026
Export OLMA’s income statement to Excel — free account
Olema Pharmaceuticals, Inc.
OLMA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 19.6%, free cash flow fell 54.3% and total debt was flat, each against the same quarter a year earlier.
6.58
0.29
−4.22%
Follow OLMA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
9.95 | 10.50 | 12.33 | 12.62 | 32.23 | 74.62 | 0.07 | 16.13 | — |
Net Debt/EBITDA |
2.82 | 3.06 | 2.50 | 1.90 | 4.01 | 15.73 | 0.02 | 1.52 | — |
Debt/Assets |
0.56% | 0.00% | 0.00% | 0.72% | 0.80% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.01 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.90 | 0.81 | 0.87 | 0.78 | 0.71 | 0.83 | 0.71 | 0.99 | — |
Capex/Depreciation |
0.00 | (0.40) | 0.04 | (1.02) | (3.59) | (5.09) | 0.00 | 0.00 | — |
Interest Coverage |
— | — | — | (48.02) | (161.74) | (32.97) | (617.57) | (74.25) | — |
| (36.61%) | (39.07%) | (42.82%) | (43.47%) | (22.83%) | (14.65%) | 51.16% | 26.04% | — | |
| (33.00%) | (35.57%) | (39.24%) | (40.97%) | (22.26%) | (13.99%) | (253.66%) | (134.33%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(35.04%) | (32.64%) | (39.47%) | (54.48%) | (25.11%) | (7.11%) | 345.56% | (71.63%) | — |
Average Days of Receivables |
— | — | — | 0.00 | — | — | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | 0.00% | — |
Free Cash Flow per Share |
(1.69) | (1.78) | (1.85) | (2.06) | (1.32) | (2.84) | (1.19) | (0.86) | — |
Cash per Share |
5.81 | 7.39 | 5.79 | 5.11 | 7.27 | 48.22 | 0.03 | 1.25 | — |
Shareholders Equity per Share |
5.50 | 6.96 | 5.61 | 4.94 | 7.20 | 48.16 | (0.48) | 1.22 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
5.50 | 6.96 | 5.61 | 4.94 | 7.20 | 48.16 | (0.48) | 1.22 | — |
Free Cash Flow |
(146.72) | (104.51) | (83.71) | (82.43) | (52.26) | (19.92) | (3.08) | (2.18) | — |
Working Capital |
463.65 | 396.72 | 244.89 | 192.35 | 281.67 | 337.55 | (1.27) | 3.04 | — |
Capital Expenditures |
— | (0.16) | 0.01 | (0.36) | (1.57) | (0.06) | — | — | — |
Net Current Asset Value |
460.58 | 396.46 | 243.46 | 190.80 | 279.31 | 337.55 | (1.27) | 3.04 | — |
| Other line items | |||||||||
Quick Ratio |
9.76 | 10.40 | 12.11 | 12.35 | 31.85 | 73.84 | 0.05 | 15.67 | — |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.30 | 0.15 | 0.35 | 0.31 | — |
Cash ROIC |
(14.86%) | (12.40%) | (16.23%) | (20.43%) | (9.10%) | (2.94%) | 261.54% | (34.99%) | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(1.69) | (1.78) | (1.85) | (2.05) | (1.28) | (2.83) | (1.19) | (0.86) | — |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | (0.04) | (0.01) | 0.00 | 0.00 | — |
Average Payables |
6.86 | 3.58 | 1.54 | 0.20 | 0.37 | 0.83 | 0.53 | 0.53 | — |
Average Assets |
492.20 | 363.96 | 246.30 | 255.80 | 319.33 | 171.43 | 1.70 | 1.64 | — |
Average Common Equity |
443.76 | 331.43 | 225.72 | 241.06 | 311.35 | 163.77 | (8.44) | (8.44) | — |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Columns are period end dates